ReviewFrontiers in immunology2020
Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Association between receiving Covid-19 vaccine and menstrual cycle patterns among childbearing women: A cross-sectional study.Health science reports · 2024Article
- Dexmedetomidine alleviates acute lung injury by promoting Tregs differentiation via activation of AMPK/SIRT1 pathway.Inflammopharmacology · 2023Article
- A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases.Frontiers in immunology · 2023Review
- Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study.Emerging microbes & infections · 2022Article
- The role of kidney injury biomarkers in COVID-19.Renal failure · 2022Review
- Whey protein hydrolysate mitigates both inflammation and endotoxin tolerance in THP-1 human monocytic leukemia cells.Immunity, inflammation and disease · 2022Article
- First computational design using lambda-superstrings and in vivo validation of SARS-CoV-2 vaccine.Scientific reports · 2022Article
- Single-cell immunology of SARS-CoV-2 infection.Nature biotechnology · 2022Review
- Peptide-Based Vaccines and Therapeutics for COVID-19.International journal of peptide research and therapeutics · 2022Review
- Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders.Frontiers in immunology · 2022Review
- Immunomodulation and Regenerative Capacity of MSCs for Long-COVID.International journal of molecular sciences · 2021Review
- Clinical Relevance of Elevated Soluble ST2, HSP27 and 20S Proteasome at Hospital Admission in Patients with COVID-19.Biology · 2021Article
- Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry.Journal of clinical medicine · 2021Article
- "Impact of pentaglobin in severe COVID 19 pneumonia- a prospective study."International immunopharmacology · 2021Article
- "L'histoire se répète", one size does not fit all.Intensive care medicine · 2021Article
- From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry.Antibodies (Basel, Switzerland) · 2021Article
- Liver disorders in COVID-19, nutritional approaches and the use of phytochemicals.World journal of gastroenterology · 2021Review
- Article
- Evaluation of SARS-CoV-2 Spike S1 Protein Response on PI3K-Mediated IL-8 Release.Medical sciences (Basel, Switzerland) · 2021Article
- CANPT Score: A Tool to Predict Severe COVID-19 on Admission.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 has become a worldwide pandemic caused by the novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe cases of COVID-19 have accounted for 10-20% of all infections, leading to more than 500,000 deaths. Increasing evidence has suggested that the inflammatory cytokine storm originating from the anti-SARS-CoV-2 immune response plays an important role in the pathogenesis of critically ill patients with COVID-19, which leads to mixed antagonistic response syndrome (MARS). In the early stage of severe COVID-19, systemic inflammatory response syndrome causes acute respiratory distress syndrome, multiple organ dysfunction syndrome, and even multiple organ failure. In the late stage of severe disease, increased production of anti-inflammatory cytokines drives the immune response to become dominated by compensatory anti-inflammatory response syndrome, which leads to immune exhaustion and susceptibility to secondary infections. Therefore, precise immunomodulation will be beneficial for patients with severe COVID-19, and immunosuppressive or immune enhancement therapy will depend on the disease course and immune status. This review summarizes the current understanding of the immunopathogenesis of severe COVID-19, especially the role of the inflammatory cytokine storm in disease progression. Immune indicators and immunotherapy strategies for severe COVID-19 are reviewed and the potential implications discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.